Myron Kaplan
CIK: 0001672645
Myron Kaplan's purchase track record
How the stock did after each of Myron Kaplan's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since November 16, 2021
Stock higher 6 months later
0%
3 months: 25%
Median 6-month return
-20.5%
3 months: -14.2%
Beat the S&P 500
0%
median -17.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/23/2025 | CRMD | $276K | -34.2% | -35.2% | +5.5% |
| 5/18/2023 | CRMD | $27K | -7.7% | -14.4% | +7.4% |
| 5/17/2022 | CRMD | $19K | +12.0% | -3.4% | -2.4% |
| 11/16/2021 | CRMD | $51K | -20.8% | -26.5% | -13.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRMD | ▲ Buy | Grant | 30,453 | $0 | 1/26/2026 | View on chart |
| CRMD | ▲ Buy | Open Market | 25,000 | $276K | 10/23/2025 | View on chart |
| CRMD | ▲ Buy | Grant | 25,000 | $0 | 1/17/2025 | View on chart |
| CRMD | ▲ Buy | Open Market | 6,000 | $27K | 5/18/2023 | View on chart |
| CRMD | ▲ Buy | Open Market | 5,000 | $19K | 5/17/2022 | View on chart |
| CRMD | ▼ Sell | Gift | 20,000 | $0 | 12/27/2021 | View on chart |
| CRMD | ▼ Sell | Gift | 5,000 | $0 | 12/27/2021 | View on chart |
| CRMD | ▼ Sell | Gift | 5,000 | $0 | 12/27/2021 | View on chart |
| CRMD | ▼ Sell | Gift | 5,000 | $0 | 12/27/2021 | View on chart |
| CRMD | ▲ Buy | Open Market | 10,000 | $51K | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CRMD: No direct news in the last week
Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.
CRMD: No direct news in the last week. Recent headlines involve Actinium Pharmaceuticals, not CorMedix Inc. There are no events that directly affect CRMD’s operations or market position. Investors can continue to monitor CRMD’s own performance and broader market conditions.